Strategy & Commercialization (4)

Challenge: The commercialization arm of a leading university wished to identify its most promising therapeutic programs within its purview in order to allocate internal translational funding to...

Challenge: A European immune-oncology biotech with a proprietary platform had generated a broad and deep pipeline of oncology assets, which had demonstrated an advantage due to their ability to...

Challenge: An Israeli university technology transfer organization asked Alacrita to explore the different potential commercialization pathways for a novel platform technology. The overall effect of...

Challenge: Alacrita was engaged by a biopharma company developing a therapeutic for a severe orphan disorder. With Breakthrough status designation from the FDA and a Prime designation from the EMA,...

Challenge: A biotechnology company developing proprietary synthetic biology technology in gene therapy expression for several clients was looking to evolve its business model. The company engaged...

Challenge: A university research group had discovered a new pathway for regulation of T cell trafficking in the inflammatory response. The group had also identified an anti-inflammatory peptide and...

Challenge A leading private US academic institution, recognizing the need to further develop early discoveries from the university in order to facilitate industry partnerships and clinical...

Challenge A privately held specialty pharmaceutical company focused in the field of psychiatry was conducting a Phase III clinical evaluation of its new formulation (one-per-day) of a commonly...

Challenge A Spanish university spinout with an integrated platform to discover and develop new antimicrobials and adjuvants with novel mechanisms of action, was advancing a potentiator program that...

Challenge Our client was a leading UK Research Institute requiring assistance in assigning internal commercialization funding to the most promising research groups within the University. Alacrita was...

Challenge Our client was a leading UK Research Institute requiring assistance in assigning internal commercialization funding to the most promising research groups within the University. Alacrita was...

Challenge A leading UK University was developing an innovative technology to permit the creation of surface-immobilized functional RNAs in a microarray format, by transcription and ‘printing’ from...